Drug Trial Radar · NCT07246564
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Actual
Start
Dec 1, 2025
Primary completion
Jun 3, 2027
Study completion Jun 3, 2027
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
Conditions
- Myasthenia Gravis
Interventions
RozanolixizumabDrug
Subcutaneous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score in the first Treatment CycleTime frame: Baseline to Day 43 (in first treatment cycle)
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Mg0033 20040
Beijing, China
Mg0033 20261
Changchun, China
Mg0033 20295
Changsha, China
Mg0033 20348
Fuzhou, China
Mg0033 20269
Guangzhou, China
Mg0033 20185
Jinan, China
Mg0033 20347
Jinan, China
Mg0033 20172
Shanghai, China
Mg0033 20184
Shenzhen, China
Mg0033 20204
Suzhou, China
Mg0033 20180
Wuhan, China
Mg0033 20349
Xuzhou SHI, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.